Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
Patients might switch from injection to oral for convenience reasons, or from oral to injection for greater efficacy
For patients with Type 2 diabetes who also have or are at high risk for cardiovascular disease, GLP-1 agonists offer a dual benefit that insulin cannot match
These could indicate serious conditions such as pancreatitis or gallbladder disease, which have been associated with GLP-1 receptor agonists in rare cases
Assessed 15 May 2021
The role of tirzepatide, dual GIP and GLP-1 Receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials
US$ 20.88
US$ 22.34
US$ 23.72
US$ 26.16
US$ 20.62
US$ 28.66
US$ 28.63
